DelSiTech is an innovative drug delivery and development company that works with its partners to turn their active agents into novel and commercially attractive therapeutic drug products.
DelSiTech provides the technology and expertise for solving drug delivery problems. The company’s technology is based on amorphous silica (SiO2) matrix and sol-gel encapsulation technique which have significant competitive advantages over other technologies.
In addition, the company is developing its own pipeline of supergeneric/505(b)(2) products to address significant unmet medical and commercial needs. The lead product, a long acting antiviral product for chronic hepatitis B, will enter the clinic in 2023.